(Q24240782)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

0 references

1 reference

title

Bisphosphonate therapy for osteogenesis imperfecta (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

main subject

osteogenesis imperfecta

0 references

author

Robert D. Steiner

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

2

Tracey Remmington

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

author name string

Carrie A Phillipi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

publication date

8 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

15 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

CD005088

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

Intravenous neridronate in adults with osteogenesis imperfecta

15 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Impact of alendronate on quality of life in children with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Growth hormone treatment in osteogenesis imperfecta with quantitative defect of type I collagen synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Early bisphosphonate treatment in infants with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Single-dose pharmacokinetics and tolerability of alendronate 35- and 70-milligram tablets in children and adolescents with osteogenesis imperfecta type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Osteogenesis imperfecta: translation of mutation to phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Osteogenesis imperfecta: perspectives and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Type V osteogenesis imperfecta: a new form of brittle bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Systematic reviews in health care: Assessing the quality of controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Hearing loss in Finnish adults with osteogenesis imperfecta: a nationwide survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Genetic heterogeneity in osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Intravenous Neridronate in Children With Osteogenesis Imperfecta: A Randomized Controlled Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

Lethal neonatal chondrodysplasias in the West of Scotland 1970-1983 with a description of a thanatophoric, dysplasialike, autosomal recessive disorder, Glasgow variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

7 January 2021

Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

7 January 2021

Effects of withdrawal of bracing in matched pairs of children with osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

7 January 2021

Do bisphosphonates make children's bones better or brittle?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

7 January 2021

Osteogenesis imperfecta

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005088.PUB2

7 January 2021

10.1002/14651858.CD005088.PUB2

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3252987

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18843680%20AND%20SRC:MED&resulttype=core&format=json

OpenCitations bibliographic resource ID

15 January 2020

3252987

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

3252987

1 reference